Achieving one of its key goals for 2008, Cell Genesys Inc. partnered its late-stage cancer vaccine, GVAX, with Japanese firm Takeda Pharmaceutical Co. Ltd. in a potential $320 million deal that puts a much-needed notch in the win column for the cancer immunotherapy space. (BioWorld Today)